Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis

Schniering, Janine; Guo, Li; Brunner, Matthias; Schibli, Roger; Ye, Shuang; Distler, Oliver; Béhé, Martin; Maurer, Britta

doi:10.1186/s13075-018-1681-1

Cited by 22 publications

(19 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In future, lung ultrasound may be integrated with other approaches in the screening of ILD [48][49][50][51]. Preclinical studies of positron emission tomography scanning suggest that targeted nuclear imaging of components of ILD disease processes (such as integrin alpha-v-beta-3 and somatostatin receptor 2) could be integrated with other approaches in the screening and evaluation of ILD [52,53]. However, this method is limited by the high levels of radiation exposure associated with the technique.…”

Section: Future Directions In the Diagnosis And Screening Of Ssc-ildmentioning

confidence: 99%

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Assassi²,

et al. 2020

Self Cite

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a systemic autoimmune disease affecting multiple organ systems, including the lungs. Interstitial lung disease (ILD) is the leading cause of death in SSc.There are no valid biomarkers to predict the occurrence of SSc-ILD, although auto-antibodies against anti-topoisomerase I and several inflammatory markers are candidate biomarkers that need further evaluation. Chest auscultation, presence of shortness of breath and pulmonary function testing are important diagnostic tools, but lack sensitivity to detect early ILD. Baseline screening with high-resolution computed tomography (HRCT) is therefore necessary to confirm an SSc-ILD diagnosis. Once diagnosed with SSc-ILD, patients' clinical courses are variable and difficult to predict, although certain patient characteristics and biomarkers are associated with disease progression. It is important to monitor patients with SSc-ILD for signs of disease progression, although there is no consensus about which diagnostic tools to use or how often monitoring should occur. In this article, we review methods used to define and predict disease progression in SSc-ILD.There is no valid definition of SSc-ILD disease progression, but we suggest that either a decline in forced vital capacity (FVC) from baseline of ≥10%, or a decline in FVC of 5–9% in association with a decline in diffusing capacity of the lung for carbon monoxide of ≥15% represents progression. An increase in the radiographic extent of ILD on HRCT imaging would also signify progression. A time period of 1–2 years is generally used for this definition, but a decline over a longer time period may also reflect clinically relevant disease progression.

show abstract

Section: Future Directions In the Diagnosis And Screening Of Ssc-ildmentioning

confidence: 99%

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Assassi²,

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…fibroblasts and activated macrophages) and/or molecules (i.e. integrin) of ILD [69][70][71] have the potential to match a pathophysiologic phenotype with a targeted therapy thereby allowing patient stratification according to predicted drug response. In addition, the in-depth analysis of routine HRCT by dedicated software, allows the generation of quantitative metadata (i.e.…”

Section: Future Perspectivesmentioning

confidence: 99%

Circulating biomarkers of systemic sclerosis – interstitial lung disease

Hoffmann‐Vold

Fretheim

Meier

et al. 2020

Journal of Scleroderma and Related Disorders

Self Cite

View full text Add to dashboard Cite

Interstitial lung disease is a frequent organ manifestation in systemic sclerosis and is associated with high mortality. It is crucial to diagnose interstitial lung disease in systemic sclerosis and to assess severity and identify patients prone to progression at an early stage to ultimately decrease organ damage and improve outcome. Circulating anti-topoisomerase-I autoantibodies have long been associated with the presence and development of systemic sclerosis – interstitial lung disease, evidence on their potential to further predict the clinical course of systemic sclerosis is however conflicting. C-reactive protein is a marker of infection and systemic inflammation with widespread clinical application and is elevated in systemic sclerosis with a tendency towards higher abundancy in patients with early disease. The role of other circulating biomarkers is promising but hampered by the lack of standardized criteria and guidelines for sample/data collection, analyses, reporting and validation and has not reached prime time for clinical application. However, epithelial markers including Krebs von den Lungen-6 and surfactant protein D and several cytokines and chemokines including CCL2 and CCL18 for severity assessment of systemic sclerosis – interstitial lung disease patients at the time of interstitial lung disease diagnosis and to predict interstitial lung disease progression have been reported and seem to be promising candidate biomarkers in the future.

show abstract

“…Can be used to study various specific metabolic processes, including those involved in early ILD in SSc, depending on the radiotracer used180…”

Section: Current Diagnostic Tools For Ild In Sscmentioning

confidence: 99%

<p>Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention</p>

Fischer

Patel

Volkmann

2019

OARRR

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a progressive and often devastating disease characterized by autoimmune dysfunction, vasculopathy, and fibrosis. Interstitial lung disease (ILD) is identified in the majority of patients with SSc and is the leading cause of SSc-related mortality. Although clinical manifestations and ILD severity vary among patients, lung function typically declines to the greatest extent during the first 3–4 years after disease onset. We aim to provide an overview of SSc-associated ILD (SSc-ILD) with a focus on current and emerging tools for early diagnosis of ILD and current and novel treatments under investigation. Early detection of ILD provides the opportunity for early therapeutic intervention, which could improve patient outcomes. Thoracic high-resolution computed tomography is the most effective method of identifying ILD in patients with SSc; it enables detection of mild lung abnormalities and plays an important role in monitoring disease progression. Cyclophosphamide and mycophenolate mofetil are the most commonly prescribed treatments for SSc-ILD. Recently, nintedanib (an antifibrotic) was approved by the Food and Drug Administration for patients with SSc-ILD; it is indicated for slowing the rate of decline in pulmonary function. However, there is a need for additional effective and well-tolerated disease-modifying therapy. Ongoing studies are evaluating other antifibrotics and novel agents. We envision that early detection of lung involvement, combined with the emergence and integration of novel therapies, will lead to improved outcomes in patients with SSc-ILD.

show abstract

Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis

Cited by 22 publications

References 53 publications

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Circulating biomarkers of systemic sclerosis – interstitial lung disease

<p>Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention</p>

Contact Info

Product

Resources

About